Welcome to our dedicated page for Anixa Biosciences SEC filings (Ticker: ANIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anixa Biosciences, Inc. filings document regulatory disclosures for a cancer-focused biotechnology company developing vaccine and CAR-T therapy programs. Recent Form 8-K reports include Regulation FD disclosures on the company's ovarian cancer CAR-T program, lira-cel, and its investigational breast cancer vaccine, including related press releases and scientific-presentation exhibits.
The company's proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, common-stock voting results, and other governance matters. These filings provide the formal record for Anixa's public-company reporting around clinical-program updates, stockholder actions, and corporate oversight.
Anixa Biosciences (ANIX) reported continued operating losses but states it has sufficient liquidity for over 12 months. The company recorded net losses of $2.3 million for the three months and $8.3 million for the nine months ended July 31, 2025, with losses from operations of $2.4 million and $8.8 million, respectively. Cash, cash equivalents and short-term investments totaled $16,029,000 at July 31, 2025, down from approximately $19,924,000 at October 31, 2024, a reduction of about $3.9 million for the nine months. During the period the company raised approximately $1.924 million, net, from an at-the-market equity offering of 611,686 shares and issued options under its 2018 Share Incentive Plan (1,430,000 granted during the nine months). Stock-based compensation was $829,000 and $2,822,000 for the three- and nine-month periods, respectively. The company continues a 2,000 sq. ft. operating lease for its San Jose office with base rent of approximately $5,000 per month.
Form 4 filing for Anixa Biosciences (ANIX): Company director Lewis H. Titterton, Jr. bought 10,000 common shares on 07/31/2025 at $3.08 per share, an outlay of roughly $30.8 k.
The purchase lifts his direct holding to 953,334 shares. No sales or derivative transactions were disclosed. Because directors are presumed to possess intimate knowledge of corporate prospects, open-market buying is generally interpreted as a positive signal of confidence rather than a routine option exercise.
Form 4 filing overview: On 07/11/2025, Anixa Biosciences (ANIX) Chief Executive Officer Amit Kumar executed an open-market purchase (Code “P”) of 5,000 common shares at $3.15 per share, an aggregate value of roughly $15,750.
Following the transaction, Kumar’s direct ownership increased to 574,925 shares. No derivative securities were reported and the filing was submitted as a single-person report on 07/14/2025.
The purchase represents a ~0.9% increment to Kumar’s previously held position and signals a modest vote of confidence from the company’s most senior executive. However, given the limited dollar amount relative to both his existing stake and the company’s overall share count, the transaction is unlikely to be viewed as a materially game-changing event by the market.